References
- Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? Pharmacoeconomics 1996;9:484–96
- Manek NJ, Lane NE. Osteoarthritis: current concepts in diagnosis and management. Am Fam Physician 2000;61:1795–804
- Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903–11
- Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 2000;27:1648–55
- Tamblyn R, Berkson L, Dauphinee D, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429–38
- Spencer-Green G, Spencer-Green E. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures. J Rheumatol 1998;25:2088–93
- Holt WS, Mazzuca SA. Prescribing behaviors of family physicians in the treatment of osteoarthritis. Fam Med 1992;24:524–7
- McMahon A, Evans J, White G, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol 1997;50:351–6
- Griffin MR, Piper J, Daugherty J, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increase risk for peptic ulcer disease in elderly patients. Ann Intern Med 1991;114:257–63
- Smalley WE, Ray WA, Daugherty J, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalization for peptic ulcer disease in elderly patients. Am J Epidemiol 1995;141:539–45
- Lapane KL, Spooner JJ, Mucha L, Straus WL. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long term care. J Am Geriatr Soc 2001;49:577–84
- Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992;92(Suppl):21–4
- Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99
- Pertusi RM, Godwin KS, House JK, et al. Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners. J Am Osteopath Assoc 1999;99:305–10
- Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8
- Watson DJ, Harper SE, Zhao P, Quan H, Bolognese JA, Simon TA. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with non-selective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998–3003
- Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921–8
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247–55
- Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595–602
- Kephart G, Seketris I, Smith M, Maheu A, Brown M. Coprescribing of nonsteroidal anti-inflammatory drugs and cyto-protective and antiulcer drugs in Nova Scotia’s senior population. Clin Ther 1995;17:1159–73